Engineered nanoparticle bio-conjugates toxicity screening: The xCELLigence cells viability impact

Area of Science:

• Biomaterials Science
• Nanotechnology
• Toxicology

Background:

• Engineered nanoparticle bio-conjugates (ENPBCs) have diverse applications, but limited data exists to support risk assessments.
• Ensuring consumer safety and understanding the risks associated with ENPBCs is critical as their market presence grows.

Purpose of the Study:

• To review and analyze existing literature on the in vitro and in vivo toxicity of ENPBCs.
• To identify the extent of data available for risk estimation and consumer safety concerns related to ENPBCs.

Main Methods:

• Systematic literature search for articles published between 2013-2016 using xCELLigence real-time cell analysis (RTCA) for in vitro ENPBC toxicity.
• Literature search for articles published between 2008-2016 on in vivo animal models assessing ENPBC toxicity and safety outcomes.
• Inclusion criteria focused on studies providing in vitro or in vivo toxicity data for ENPBCs.

Main Results:

• Out of 121 identified articles, 32 met the inclusion criteria (23 for in vitro, 9 for in vivo).
• Most in vitro studies (19/23) using xCELLigence technology indicated ENPBCs were non-toxic or partially non-toxic.
• In vivo studies showed limited potential toxicity in one case, with others suggesting ENPBCs as drug therapy candidates but lacking comprehensive toxicity data.

Conclusions:

• Current data on the bioimpacts of ENPBCs, both in vitro and in vivo, remains limited.
• Further in vitro and in vivo assays, clinical trials, and long-term impact studies are necessary to validate ENPBC safety and facilitate their uptake.
• Enhanced real-time analysis using technologies like xCELLigence is needed to generate robust data for subsequent in vivo investigations.